Tri Locum Partners’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27M Sell
118,384
-140,356
-54% -$35.6M 5.33% 8
2026
Q2
$69M Buy
258,740
+3,408
+1% +$796K 8.49% 4
2026
Q1
$58.4M Sell
255,332
-9,683
-4% -$2.17M 8.2% 4
2025
Q4
$56.5M Buy
265,015
+90,186
+52% +$18.6M 7.34% 5
2025
Q3
$34.8M Buy
174,829
+27,187
+18% +$5.07M 7.99% 5
2025
Q2
$25.5M Buy
147,642
+115,317
+357% +$18.8M 7.73% 5
2025
Q1
$5.04M Buy
+32,325
New +$4.62M 2.59% 15
2024
Q3
– Sell
-227,762
Closed -$31.1M – 23
2024
Q2
$31.1M Buy
227,762
+115,092
+102% +$15.7M 7.85% 3
2024
Q1
$17M Buy
112,670
+13,120
+13% +$1.87M 5.91% 5
2023
Q4
$12.5M Buy
+99,550
New +$9.9M 5.73% 6
2023
Q1
– Sell
-99,215
Closed -$12.1M – 53
2022
Q4
$12.1M Buy
+99,215
New +$11.5M 4.9% 7

Other funds holding ASND

Tri Locum Partners's ASND Position: Q3 2026 in Review

Tri Locum Partners reduced its Ascendis Pharma (ASND) stake by 54% in Q3 2026, selling an estimated $35.6M and leaving 118,384 shares worth $27M. The position accounts for 5.33% of the portfolio, ranked #8.

Tri Locum Partners first reported a position in ASND in Q4 2022 and has held it in 11 quarters since. The position peaked at $69M in Q2 2026. 347 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Tri Locum Partners held 118,384 shares of Ascendis Pharma worth $27M as of Q3 2026.
  • Tri Locum Partners sold 140,356 Ascendis Pharma shares in Q3 2026, an estimated $35.6M.
  • Ascendis Pharma made up 5.33% of Tri Locum Partners's portfolio in Q3 2026, its #8 holding.
  • Tri Locum Partners first reported a position in Ascendis Pharma in Q4 2022 and has held it in 11 quarters since.
  • Tri Locum Partners's Ascendis Pharma position peaked at $69M in Q2 2026.
  • 347 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on Tri Locum Partners's 13F filing for Q3 2026, filed 16 Nov 2026.